Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | OGA | O60502 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15652641 | 0.74 | PIM1 (0.38) | SCN9A | |
| SCHEMBL17761016 | 0.71 | HPGD (0.46) | HTR2BCYP2C19ACHEHRH3 | |
| SCHEMBL3262633 | 0.70 | HTR2B (0.44) | HTR2BSCDCYP2C19ACHECYP2C9 | |
| SCHEMBL457405 | 0.70 | HTR2B (0.44) | HTR2BCYP2C19ACHECYP2C9SCN9A | |
| SCHEMBL22048957 | 0.63 | OGA (0.52) | SCDCYP2C19HRH3CYP2C9OGA | |
| SCHEMBL28141436 | 0.62 | HRH3 (0.50) | SCDHRH3OGA | |
| SCHEMBL2745784 | 0.61 | HTR2B (0.49) | HTR2BSCDCYP2C19ACHEHRH3 | |
| SCHEMBL692035 | 0.61 | — | — | |
| SCHEMBL1788277 | 0.61 | — | — | |
| Methane SCHEMBL19899593 | 0.61 | ALDH1A1 (0.53) | HTR2BCYP2C19ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HTR2B 1922/4885SCD 4484/4885CYP2C19 2941/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HTR2B 1915/4885SCD 4689/4885CYP2C19 1846/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HTR2B 1922/4885SCD 4484/4885CYP2C19 2941/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | HTR2B 1659/4885SCD 4217/4885CYP2C19 2888/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | HTR2B 1659/4885SCD 4217/4885CYP2C19 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.